Prometheus Biosciences Current Cash

Prometheus Biosciences (RXDX) currently reports a current cash of $110M as of March 2023. That compares with $230M in the prior-year period — down 50.1% year over year. Use the charts on this page to explore Prometheus Biosciences's current cash history and peer comparisons.

Prometheus Biosciences's current cash decreased from $230M to $110M — a 50.1% year-over-year decrease (period ending March 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Prometheus Biosciences reported $110M in current cash as of March 2023. That compares with $230M in the prior-year period — down 50.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $110M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Prometheus Biosciences, and consider following RXDX for alerts when major investors trade the stock.

Prometheus Biosciences is classified in the Healthcare sector. On current cash, it currently shows $110M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RXDX with unrelated industries.